D-0143-2020 Class II Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-0143-2020 was initiated by Aurobindo Pharma USA Inc. on Sep 19, 2019 and is designated Class II. Reason for recall: Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness. The recall status is terminated (terminated Apr 4, 2023). Affected quantity: 11,129 100-count bottles.

Recall details

Product Type
Drugs
Report Date
Oct 23, 2019
Initiation Date
Sep 19, 2019
Termination Date
Apr 4, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,129 100-count bottles

Product description

Dextroamphetamine Sacharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Mixed Salts of a single Entity Amphetamine Product), 20mg, 100-count bottle, RX Only, Distributed by: Aurobindo Pharma USA Inc., Dayton, NJ 08810, NDC 13107-073-01

Reason for recall

Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness.

Distribution pattern

Nationwide in the US

Code information

Batch 07319032A1, Exp 02/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0143-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0143-2020. Report a data issue: hello@regdatalab.com.